Record-Breaking Q1 Performance

Eli Lilly announced a staggering 45% increase in first-quarter revenue for fiscal 2025, reaching $12.73 billion. This remarkable growth was primarily driven by the soaring demand for Mounjaro and Zepbound, showcasing the company's strong position in the weight-loss and diabetes drug markets.

Financial Highlights

The company also reported a net income of $2.76 billion, marking a 23% year-over-year increase. Earnings per share stood at $3.06, even after accounting for $1.57 billion in acquired in-process R&D charges. These figures underscore Eli Lilly's robust financial health and operational efficiency.

Future Outlook

CEO David Ricks shared exciting developments, including the progress of the oral GLP-1 candidate, forgilzumab. With revenue guidance for the year set between $58 billion and $61 billion, Eli Lilly is on a clear growth trajectory. Additionally, the company plans a massive $50 billion expansion of US manufacturing capabilities to cater to the escalating demand.